RECRUITING

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: * Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. * Be asked study-related questions by phone or at a clinic visit. * Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT.

Official Title

CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States

Quick Facts

Study Start:2023-11-13
Study Completion:2033-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06259292

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.
  2. * Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.
  1. * Unable to provide informed consent or informed consent via a parent or legally authorized representative.

Contacts and Locations

Study Contact

Melissa A Dickey, MSN
CONTACT
410-357-9932
melissa.dickey@curehht.org
Nolie Krock, MSc
CONTACT
410-357-9932
nolie.krock@curehht.org

Principal Investigator

Melissa A Dickey, MSN
PRINCIPAL_INVESTIGATOR
Cure HHT

Study Locations (Sites)

University of California, Los Angeles
Los Angeles, California, 90095
United States
University of California, San Francisco
San Francisco, California, 94107
United States
University of Colorado, Denver
Aurora, Colorado, 80045
United States
Yale University
New Haven, Connecticut, 06520
United States
Augusta University
Augusta, Georgia, 30912
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
Washington University School of Medicine
Saint Louis, Missouri, 63110
United States
Columbia University
New York, New York, 10032
United States
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599
United States
The Cleveland Clinic
Cleveland, Ohio, 44106
United States
Oregon Health and Science University
Portland, Oregon, 97239
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
University of Texas Southwestern
Dallas, Texas, 75390
United States
University of Utah
Salt Lake City, Utah, 84132
United States

Collaborators and Investigators

Sponsor: Cure HHT

  • Melissa A Dickey, MSN, PRINCIPAL_INVESTIGATOR, Cure HHT

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-13
Study Completion Date2033-11

Study Record Updates

Study Start Date2023-11-13
Study Completion Date2033-11

Terms related to this study

Additional Relevant MeSH Terms

  • Hereditary Hemorrhagic Telangiectasia
  • Arteriovenous Malformations
  • Telangiectasia
  • Epistaxis
  • GastroIntestinal Bleeding
  • Cerebral Arteriovenous Malformations
  • Vascular Malformation